Progress in the development of immunotherapy for the treatment of patients with cancer.
about
The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-alpha, IFN-gamma and iNOS mRNANeoplastic "Black Ops": cancer's subversive tactics in overcoming host defensesAntitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentationSEREX identification of new tumour-associated antigens in cutaneous T-cell lymphomaCytokine-related genes identified from the RIKEN full-length mouse cDNA data setPersistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomesDevelopment and application of 'phosphoflow' as a tool for immunomonitoringA2A adenosine receptor protects tumors from antitumor T cells.Acupuncture May Stimulate Anticancer Immunity via Activation of Natural Killer Cells.Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.T cell-mediated immunotherapy of metastases: state of the art in 2005.Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.Tumor-infiltrating T lymphocytes: friends or foes?Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantationAdenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015CD4+ CD25+ regulatory T cells: a therapeutic target for liver diseases.Immunotherapy in colorectal cancer.Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Tumor-associated galectin-3 modulates the function of tumor-reactive T cells.Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer.From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy.Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.T cell deficiency leads to liver carcinogenesis in azoxymethane-treated rats.Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2
P2860
Q24682924-29755427-498C-4F31-ACFA-BA3CEADDBE7DQ27001081-6F6E05D9-1656-49F3-B2DE-03004B1CC14AQ27026193-AC48219E-8F26-4BA7-BF27-4D2FE15D8BABQ28247977-179C228C-1515-4E61-AAD8-89988B4CC555Q30805616-ADA24659-2550-41D8-94AB-647A612B5BB4Q33210267-0C2D99FB-A6A0-48CE-8802-E2AC20A8067BQ33240732-8153C255-2D59-4E3A-9A2E-B45C98A46B2AQ33959996-C69DF747-9FFA-4291-8569-417D97A3B9BDQ34105965-C7758C47-1EE3-453A-957E-43F284E20AE6Q35016529-19149DCC-E960-41CB-A8B2-FDCB73E79645Q35103225-AAF95636-BEF8-4AC2-BFD1-9E04B8849808Q35691891-746CF422-C095-4B9E-BDDA-63EB735FB3B0Q36210864-93502394-F6B6-4509-BB8A-D038F57FF859Q36308365-4D8746A6-CF5E-4596-99AB-1A8685405756Q36381918-FAF17940-BFE7-485D-9CD0-E90A90BDA7EEQ36423437-327C995B-E0BF-45C8-B8F8-4F424385440EQ36496998-2E74F852-DDAE-4523-AC80-AC2D15358C06Q36822947-A0EE0338-C6AD-4A45-9C61-DE210151A48DQ37082777-87F20657-4703-4762-826C-01F9046CB89CQ37280829-C43B975F-ECC2-429E-9450-CC64309EDF4CQ37873379-1DE50475-3002-47F7-A171-90E201BE4449Q38572896-F7414AD9-F075-4EC9-A7E7-BD0518C78961Q40614533-87DEE520-7B0D-4089-B18E-A14F5115B2DCQ40729839-AB28A119-E2D7-4D07-B34C-719ECA0D1947Q41849280-0A506EEA-4EF3-4AD2-83D3-2324FDC5ABA7Q42428717-242597A6-DE58-423E-8C6A-1F8C45CBC16FQ43183021-A053CA0C-30C5-4ACE-AD0A-FA5309D7AF8FQ50769076-536E19C1-43A5-4DEA-8352-A12EBF82E75AQ53350855-C617D6A9-0BF7-4860-B3FC-432849B3E080Q54252958-CDA44D98-41EC-408A-9E97-86F2670085F2Q54305120-E8CE993B-24ED-487E-9038-32F89D737264Q58700691-5D602DFC-5EF6-44ED-B94C-55257376320B
P2860
Progress in the development of immunotherapy for the treatment of patients with cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Progress in the development of immunotherapy for the treatment of patients with cancer.
@ast
Progress in the development of immunotherapy for the treatment of patients with cancer.
@en
Progress in the development of immunotherapy for the treatment of patients with cancer.
@nl
type
label
Progress in the development of immunotherapy for the treatment of patients with cancer.
@ast
Progress in the development of immunotherapy for the treatment of patients with cancer.
@en
Progress in the development of immunotherapy for the treatment of patients with cancer.
@nl
prefLabel
Progress in the development of immunotherapy for the treatment of patients with cancer.
@ast
Progress in the development of immunotherapy for the treatment of patients with cancer.
@en
Progress in the development of immunotherapy for the treatment of patients with cancer.
@nl
P2860
P1476
Progress in the development of immunotherapy for the treatment of patients with cancer.
@en
P2093
S A Rosenberg
P2860
P304
P356
10.1046/J.1365-2796.2001.00911.X
P407
P577
2001-12-01T00:00:00Z